Bio-Techne's Ultra-Sensitive Assays Target Early Neurodegenerative Disease Detection
Event summary
- Bio-Techne launched Simple Plex Ultra-Sensitive Assays on its Ella platform on January 28, 2026.
- The assays enable femtogram-level detection of neurological biomarkers like NFL, GFAP, pTau 217, and Amyloid β (aa1-42).
- The Ella platform, already cited in over 1,000 peer-reviewed publications, features an automated workflow with a runtime under three hours.
- The assays are intended for Research Use Only and build upon Bio-Techne's existing portfolio, which generated over $1.2 billion in net sales in fiscal 2025.
The big picture
Bio-Techne's move underscores the growing demand for earlier and more precise diagnostics in neurodegenerative diseases, a market driven by an aging population and increasing research investment. The femtogram-level sensitivity represents a significant technological leap, potentially enabling earlier intervention and improved therapeutic outcomes. This launch strengthens Bio-Techne’s position in the broader life sciences tools market, which is increasingly focused on personalized and precision medicine approaches.
What we're watching
- Adoption Rate
- The speed at which research institutions and pharmaceutical companies adopt these assays will determine the immediate impact on Bio-Techne's Protein Sciences segment revenue.
- Clinical Validation
- Successful clinical validation of the assays' ability to predict disease progression will be crucial for broader adoption and potential diagnostic applications beyond research.
- Competitive Landscape
- How competitors respond with similar ultra-sensitive assays will influence Bio-Techne's pricing power and market share within the neurodegenerative disease research space.
Related topics